Trastuzumab (Herceptin): Fig 1.

Psoriasis Induced by Trastuzumab (Herceptin®)

Trastuzumab (Herceptin), a humanized monoclonal antibody, is a cancer drug developed to target the human epidermal receptor (HER) 2, which is overexpressed in some cancer cells. Cutaneous side effects, such as folliculitis, xerosis, and alopecia have not been reported with therapies targeting HER2, in spite of the frequent observances of such with the therapies targeting the epidermal growth fa...

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Clinical trials of Herceptin(R) (trastuzumab).

This report summarises the clinical efficacy and safety findings from clinical trials of the new anti-HER2 monoclonal antibody Herceptin(R) (trastuzumab). Data from pivotal trials indicate that trastuzumab is active when added to chemotherapy in patients with advanced metastatic breast cancer. In particular, the combination significantly prolonged the median time to disease progression, increas...

Trastuzumab (herceptin) for early-stage breast cancer.

Breast cancer patients who have HER2 gene amplification and, consequently, protein overexpression, generally show an aggressive course with short disease-free and overall survivals. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, has been shown to benefit patients who have HER2-positive metastatic breast cancer, and recently, the results of five ad...

Cardiotoxicity of trastuzumab (herceptin) in chick embryos.

The cardiac toxicity of trastuzumab was studied in chick embryos. Fertilized eggs of White Leghorns were incubated and investigated. Trastuzumab 5 mg/egg (low dose) or 15 mg/egg (high dose) was injected into the air sac of a fertilized egg on the 16th day of incubation. Electrocardiograms (ECGs) were recorded 0 to 60 min after the injection. After low dosing of trastuzumab, the heart rate was n...